NRX Pharmaceuticals Inc
NRXP
Company Profile
Business description
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Contact
1201 Orange Street
Suite 600
WilmingtonDE19801
USAT: +1 484 254-6134
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
29
Stocks News & Analysis
stocks
Margins have bottomed for ASX listed consumer goods company
Impact of tariffs have been priced in.
stocks
SpaceX rally continues, expanding sky-high valuations
SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,031.20 | 9.40 | 0.10% |
| CAC 40 | 8,386.38 | 34.76 | -0.41% |
| DAX 40 | 24,989.65 | 3.83 | 0.02% |
| Dow JONES (US) | 51,564.70 | 72.15 | 0.14% |
| FTSE 100 | 10,412.41 | 49.14 | 0.47% |
| HKSE | 23,768.52 | 156.29 | -0.65% |
| NASDAQ | 26,517.93 | 496.28 | 1.91% |
| Nikkei 225 | 72,353.96 | 1,103.90 | 1.55% |
| NZX 50 Index | 13,446.05 | 49.58 | -0.37% |
| S&P 500 | 7,500.58 | 80.48 | 1.08% |
| S&P/ASX 200 | 8,816.10 | 14.20 | 0.16% |
| SSE Composite Index | 4,163.10 | 72.62 | 1.78% |